AARDVARK THERAPEUTICS, INC. Operating Cash Flow
AARDVARK THERAPEUTICS, INC. (AARD) reported Operating Cash Flow of -$36.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$17.60M.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$18.87M.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$16.81M.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$16.13M.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$54.17M.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$18.09M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$36.47M 10-Q · filed 2026-08-11 | -$53.28M derived: sum of 3 quarters · filed 2026-08-11 | -$69.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$18.87M 10-Q · filed 2026-05-07 | -$35.68M derived: sum of 2 quarters · filed 2026-05-07 | -$51.81M derived: sum of 3 quarters · filed 2026-05-07 | -$61.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$16.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$32.94M derived: sum of 2 quarters · filed 2026-03-23 | -$42.78M derived: sum of 3 quarters · filed 2026-08-11 | -$54.17M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$16.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$25.97M derived: sum of 2 quarters · filed 2026-08-11 | -$37.36M 10-Q · filed 2025-11-13 | -$45.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$9.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$21.23M 10-Q · filed 2026-08-11 | -$28.96M derived: sum of 3 quarters · filed 2026-08-11 | -$32.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$11.39M 10-Q · filed 2026-05-07 | -$19.11M derived: sum of 2 quarters · filed 2026-05-07 | -$23.07M derived: sum of 3 quarters · filed 2026-05-07 | -$27.29M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$7.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$11.68M derived: sum of 2 quarters · filed 2026-03-23 | -$15.90M derived: sum of 3 quarters · filed 2026-03-23 | -$18.09M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$8.17M derived: sum of 2 quarters · filed 2025-11-13 | -$10.36M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$4.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$6.41M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$2.19M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |